A double-blind placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression

Journal of Clinical Psychiatry

Volumn 59, Issue 5, 1998, Pages 246-253

  Feighner, John ^a   Targum, Steven D ^b   Bennett, Mary Ellen ^a   Roberts, Douglas L ^c   Kensler, Terry T ^c   D'Amico, M Frances ^c   Hardy, Sterling A ^c  

^a Feighner Research Institute   (United States)

^b CROZER CHESTER MEDICAL CENTER   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEFAZODONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RATING SCALE;

EID: 0031799754     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v59n0508     Document Type: Article

References (35)

1. Klerman GL, Weissman MM, Frank E, et al. Evaluating drug treatments of depressive disorders. In: Prien RF, Robinson DS, eds. Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. New York, NY: Raven Press; 1994:281-325
2. Mazure CM, Nelson JC, Jatlow PI. Predictors of hospital outcome without antidepressants in major depression. Psychiatry Res 1990;33:51-58
3. Edwards JG. Ethics of placebo-controlled trials in depression [editorial]. Hum Psychopharmacol 1989;4:235-236
4. Edwards JG. Ethics of placebo-controlled trials in depression: a reply to a reply. Hum Psychopharmacol 1989;5:374-375
5. Lasagna L. Decision processes in establishing the efficacy and safety of psychotropic agents. In: Prien RF, Robinson DS, eds. Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. New York, NY: Raven Press; 1994:13-28
6. Manna V, Martucci N, Agnoli A. Double-blind controlled study on the clinical efficacy and safety of fluoxetine vs clomipramine in the treatment of major depressive disorders. Int Clin Psychopharmacol 1989;4(suppl 1): 81-88
7. de Jonghe F, Ravelli DP, Tuynman-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry 1991;24:62-67
8. Beasley CM, Holman SL, Potvin JH. Fluoxetine compared with imipramine in the treatment of inpatient depression. Ann Clin Psychiatry 1993;5: 199-208
9. Clerc GE, Ruimy P, Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-143
10. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299
11. Feighner JP, Boyer WF, Meredith CH, et al. A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine. Int Clin Psychopharmacol 1989;4:239-244
12. Guelfi JD, White C, Magni G. A randomized double-blind comparison of venlafaxine and placebo in inpatients with major depression and melancholia [abstract]. Clin Neuropharmacol 1992;15(suppl 1, pt B):323B
13. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994;55(9, suppl A):62-70
14. Khan MC. A randomized, double-blind, placebo-controlled, 5-weeks study of ORG-3770 (mirtazapine) in major depression. Hum Psychopharmacol 1995;10(suppl 2):S119-S124
15. Edwards JG, Goldie A. Placebo-controlled trial of paroxetine in depressive illness. Hum Psychopharmacol 1993;8:203-209
16. Eison A, Eison M, Torrente J, et al. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990;26:311-315
17. Taylor DP, Carter RB, Eison AS, et al. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 1995;56 (suppl 6):3-11
18. Feighner JP, Pambakian R, Fowler RC, et al. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychopharmacol Bull 1989;25:219-221
19. Rickels K, Schweizer E, Clary C, et al. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 1994;164: 802-805
20. Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994;55:234-241
21. Cohn CK, Robinson DS, Roberts DL, et al. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry 1996;57(suppl 2): 15-18
22. Mendels J, Reimherr F, Marcus RN, et al. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. J Clin Psychiatry 1995;56(suppl 6):30-36
23. Baldwin DS, Hawley CJ, Abed RT, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996;57(suppl 2):46-52
24. Feiger A, Kiev A, Shrivastava RK, et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57(suppl 2):53-62
25. Rioux P, Kibleur Y, Frachon O, et al. A double-blind comparison of nefazodone and fluoxetine in depressed patients. In: New Research Program and Abstracts of the 149th Annual Meeting of the American Psychiatric Association; May 7, 1996; New York, NY. Abstract NR359:164
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1994
27. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville. Md: National Institute of Mental Health; 1976:179-222
28. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
29. Kocsis JH, Croughan JL, Katz MM, et al. Response to treatment with anti-depressants of patients with severe or moderate nonpsychotic depression and of patients with psychotic depression. Am J Psychiatry 1990;147: 621-624
30. Hirschfeld RA. Diagnosing severely depressed patients in clinical trials and in clinical settings. pp 554-556. In: Controversies in the Diagnosis and Treatment of Severe Depression [ACADEMIC HIGHLIGHTS]. J Clin Psychiatry 1996;57:554-561
31. Coryell W, Endicott J, Keller MB. Outcome of patients with chronic affective disorder: a five-year follow-up. Am J Psychiatry 1990;147: 1627-1633
32. Keller MB, Harrison W, Fawcett JA, et al. Mood disorders. Psychopharmacol Bull 1995;31(2):205-212
33. Howland RH. Chronic depression. Hosp Community Psychiatry 1993;44: 633-639
34. Karasu TB, chair, for the Work Group on Major Depressive Disorder. Practice Guideline for Major Depressive Disorder in Adults. Am J Psychiatry 1993;150(suppl 4):1-26
35. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995;56(suppl 6):12-21